-
Signature
-
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact
-
Issuer symbol
-
RNA
-
Transactions as of
-
06 Aug 2025
-
Net transactions value
-
-$2,717,331
-
Form type
-
4
-
Filing time
-
08 Aug 2025, 17:41:14 UTC
Reporting Owners (1)
| Name |
Relationship |
Address |
Signature |
Signature date |
CIK |
| LEVIN ARTHUR A |
Director |
C/O AVIDITY BIOSCIENCES, INC., 10578 SCIENCE CENTER DRIVE, SUITE 125, SAN DIEGO |
/s/ John B. Moriarty, Jr., J.D., Attorney-in-Fact |
08 Aug 2025 |
0001181556 |
Transactions Table
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Ownership |
Footnotes |
| transaction |
RNA |
Common Stock |
Options Exercise |
$2,401,550 |
+107,500 |
+547% |
$22.34 |
127,150 |
06 Aug 2025 |
Direct |
F1 |
| transaction |
RNA |
Common Stock |
Sale |
$5,118,881 |
-107,500 |
-85% |
$47.62 |
19,650 |
06 Aug 2025 |
Direct |
F1, F2 |
| holding |
RNA |
Common Stock |
|
|
|
|
|
131,372 |
06 Aug 2025 |
By family trust |
|
| holding |
RNA |
Common Stock |
|
|
|
|
|
22,500 |
06 Aug 2025 |
By charitable remainder trust |
|
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type |
Sym |
Class |
Transaction |
Value $ |
Shares |
Change % |
* Price $ |
Shares After |
Date |
Underlying Class |
Amount |
Exercise Price |
Ownership |
Footnotes |
| transaction |
RNA |
Stock Option (Right to Buy) |
Options Exercise |
$0 |
-107,500 |
-90% |
$0.000000 |
12,500 |
06 Aug 2025 |
Common Stock |
107,500 |
$22.34 |
Direct |
F1, F3 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
Explanation of Responses: